FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a KMT2A Translocation By Ogkologos - December 10, 2024 892 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AUGMENT-101 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the European Parliament’s (EP) Call for a Sustainable Cancer Workforce to Deliver Quality Care for Patients with Cancer ESMO Welcomes the Inclusion of Tobacco Provisions in European Parliament’s Report on Cardiovascular Diseases and Calls for Additional Measures to Prevent Cancer Perioperative Durvalumab Continues to Show Clinical Benefit in Patients with Resectable Stage IIA to IIIB NSCLC MOST POPULAR Doctor Said Her Mammogram Results Were Normal, But Now She’s Fighting... August 25, 2020 Promising Results Observed with Front-line Sintilimab Plus a Bevacizumab Biosimilar in... November 21, 2020 Health of Gut Microbes May Affect Survival after Stem Cell Transplant March 25, 2020 From smart knives to virtual reality tumours: five innovations in understanding... August 29, 2022 Load more HOT NEWS Woman Diagnosed with Cancer a Week After Her Honeymoon Helps Others... POT1 Mutations Associated with Long Telomere Length Confer a Predisposition to... Screen-Detected Colorectal Cancers Have a More Favourable Stage Distribution than Colorectal... Pregnant Mom Had to Fight for a Diagnosis After Finding a...
